P
ABCL icon

&Partners’s AbCellera Biologics ABCL Stock Holding History

&Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.9K Hold
10,000
– – ﹤0.01% 2372
2025
Q4 		$34.2K Sell
10,000
-5,000
-33% -$22.3K ﹤0.01% 2252
2025
Q3 		$75.5K Buy
+15,000
New +$66.1K ﹤0.01% 2065

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

&Partners's ABCL Position: Q1 2026 in Review

&Partners held its AbCellera Biologics (ABCL) position steady in Q1 2026 at 10,000 shares worth $34.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2372.

&Partners first reported a position in ABCL in Q3 2025 and has held it in 3 quarters since. The position peaked at $75.5K in Q3 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • &Partners held 10,000 shares of AbCellera Biologics worth $34.9K as of Q1 2026.
  • &Partners left its AbCellera Biologics share count unchanged in Q1 2026.
  • AbCellera Biologics made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #2372 holding.
  • &Partners first reported a position in AbCellera Biologics in Q3 2025 and has held it in 3 quarters since.
  • &Partners's AbCellera Biologics position peaked at $75.5K in Q3 2025.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.